Novavax Inc. (NASDAQ:NVAX) SVP John Trizzino acquired 46,000 shares of the stock in a transaction dated Thursday, September 22nd. The shares were purchased at an average price of $2.17 per share, for a total transaction of $99,820.00. Following the completion of the transaction, the senior vice president now owns 85,564 shares of the company’s stock, valued at approximately $185,673.88. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Novavax Inc. (NASDAQ:NVAX) opened at 2.26 on Monday. The firm has a 50-day moving average price of $6.38 and a 200-day moving average price of $6.11. The firm’s market cap is $612.08 million. Novavax Inc. has a 1-year low of $1.16 and a 1-year high of $9.23.
Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.04. Novavax had a negative net margin of 1,405.84% and a negative return on equity of 112.45%. The business earned $2.50 million during the quarter, compared to analyst estimates of $8.03 million. During the same period in the previous year, the business earned ($0.08) earnings per share. The business’s quarterly revenue was down 82.1% on a year-over-year basis. On average, analysts expect that Novavax Inc. will post ($1.09) earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in NVAX. Coldstream Capital Management Inc. boosted its stake in Novavax by 17.5% in the second quarter. Coldstream Capital Management Inc. now owns 13,805 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 2,055 shares during the last quarter. Compagnie Lombard Odier SCmA acquired a new stake in Novavax during the second quarter worth about $102,000. Veritable L.P. acquired a new stake in Novavax during the second quarter worth about $102,000. BlackRock Inc. boosted its stake in Novavax by 138.7% in the first quarter. BlackRock Inc. now owns 19,870 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 11,547 shares during the last quarter. Finally, Parametrica Management Ltd acquired a new stake in Novavax during the first quarter worth about $107,000. 79.84% of the stock is owned by institutional investors.
A number of analysts have recently issued reports on the company. Chardan Capital restated a “hold” rating and set a $5.75 price objective on shares of Novavax in a research report on Sunday, August 14th. Citigroup Inc. boosted their price objective on Novavax from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, July 28th. Guggenheim restated a “buy” rating and set a $25.00 price objective on shares of Novavax in a research report on Monday, August 29th. Vetr upgraded Novavax from a “buy” rating to a “strong-buy” rating and set a $8.35 price objective on the stock in a research report on Tuesday, July 19th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $14.00 price objective on shares of Novavax in a research report on Friday, September 9th. Seven investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $7.06.
Novavax Company Profile
Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.